J Biol Chem, Vol. 274, Issue 45, 31967-31973, November 5, 1999
Substrate Diversity of Herpes Simplex Virus Thymidine Kinase
IMPACT OF THE KINEMATICS OF THE ENZYME*
Beatrice D.
Pilger
,
Remo
Perozzo
,
Frank
Alber§¶,
Christine
Wurth
,
Gerd
Folkers
, and
Leonardo
Scapozza
From the
Department of Pharmacy, Swiss Federal
Institute of Technology, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland and the § Instituto
Nazionale per la Fisica della Materia and ¶ International
School for Advanced Studies, Via Beirut 4, 34014 Trieste, Italy
 |
ABSTRACT |
Herpes simplex virus type 1 (HSV 1) thymidine
kinase (TK) exhibits an extensive substrate diversity for nucleobases
and sugar moieties, in contrast to other TKs. This substrate diversity
is the crucial molecular basis of selective antiviral and suicide gene
therapy. The mechanisms of substrate binding of HSV 1 TK were studied
by means of site-directed mutagenesis combined with isothermal
calorimetric measurements and guided by theoretical calculations and
sequence comparison. The results show the link between the
exceptionally broad substrate diversity of HSV 1 TK and the presence of
structural features such as the residue triad His-58/Met-128/Tyr-172.
The mutation of Met-128 into a Phe and the double mutant M128F/Y172F
result in mutants that have lost their activity. However, by exchanging
His to form the triple mutant H58L/M128F/Y172F, the enzyme regains
activity. Strikingly, this triple mutant becomes resistant toward
acyclovir. Furthermore, we give evidence for the importance of Glu-225
of the flexible LID region for the catalytic reaction. The data
presented give new insights to understand mechanisms ruling substrate
diversity and thus are crucial for both the development of new
antiviral drugs and engineering of mutant TKs apt to accept novel
substrate analogs for gene therapeutic approaches.
 |
INTRODUCTION |
Herpes simplex virus type 1 (HSV
1)1 thymidine kinase (TK) is
a multifunctional enzyme that possesses kinase activities normally performed by three separate cellular enzymes. It phosphorylates thymidine (dT), which is then transformed by cellular kinases to the
triphosphorylated DNA building block, and deoxyuridine (dU); both
reactions are comparable to the function of human cellular TK. Further,
it converts deoxycytidine (dC) to dCMP, as does human deoxycytidine
kinase (dCK), and phosphorylates thymidylate (dTMP), as does human TMP
kinase (TmpK) (1-3). Moreover, unlike its cellular counterpart human
cellular TK, HSV 1 TK is able to phosphorylate pyrimidine, as well as
purine analogs, and discloses low stereochemical demands for the ribose
moiety, as it also accepts acyclic side chains as phosphoryl group
acceptors e.g. (4-6). These differences in substrate
diversity are the crucial molecular basis for the selective treatment
of viral infections. Nowadays, the most widely used therapeutic
compounds to interfere with a severe HSV 1 infection are the purine
analogs acyclovir (ACV) and penciclovir and their prodrugs valaciclovir
and famciclovir, respectively. They require HSV 1 TK to be efficiently
activated in order to block virus proliferation by inhibition of viral
DNA polymerase. HSV 1 TK is the key enzyme in this antiviral strategy.
In gene therapy of cancer (7, 8) and AIDS (9), HSV 1 TK is used as a
suicide enzyme in combination with the purine analog ganciclovir.
Another important application is the use of HSV 1 TK as a rescue system
in allogeneic bone marrow transplantation-induced graft
versus host disease (10). In addition to the significance
from a therapeutic point of view, HSV 1 TK seems to be important for
the reactivation of the virus from lifelong latent infection in
neuronal ganglia (11-13). However, there is evidence that human TK can
functionally replace viral TK in terms of reactivation of the virus
from latency (14).
There are no recognizable sequence similarities between HSV 1 TK and
human cellular TK (15). Rather, sequence alignments have detected
similarities between herpesvirus TKs and human dCK (16) and to a lesser
extent cellular TmpK (17). Despite the limited sequence homology with
enzymes of the nucleotide kinase (NK) family, HSV 1 TK shares
structural features comprising a parallel five-stranded
-sheet and a
glycine-rich loop common to all NKs. In the crystal structure, HSV 1 TK
is a homodimeric enzyme with 376 amino acids per subunit (18-20). The
two subunits are related by C2 symmetry. The active site is formed by
an ATP- and a nucleoside-binding region. The visual representation of the thymidine binding site is depicted in Fig. 1, featuring a complex
hydrogen bond network within the active site. The thymine ring makes
pairwise hydrogen bond interaction via its 4-carbonyl and 3-NH group
with the amide group of the highly conserved Gln-125 and hydrogen bonds
with Arg-176 by means of two ordered water molecules. Moreover, the
pyrimidine ring of thymidine is fixed between Met-128 and Tyr-172,
forming a sandwich-like complex. His-58 and Arg-163 both interact with
the hydroxyl group of Tyr-172, sealing the position of tyrosine. The
deoxyribose makes hydrogen bond interaction via its 3'-OH with Tyr-101
and the highly conserved Glu-225 and via its 5'-OH with Glu-83. Glu-225
belongs to the LID domain, a region rich in lysine and arginine
residues that appears to be able to form a flap that encloses the
active site. This LID region is expected to undergo conformational
changes upon substrate binding and therefore influencing the catalytic phosphorylation rate, similar to ADK, with which TK shares similar three-dimensional features (21).
Up to now, various studies (see, e.g. Refs. 22-25) tried to
elucidate the role and functionality of the amino acid residues in HSV
1 TK, and with resolving of the crystal structure (18-20), pivotal
supplementary information became accessible. For example, this
structural information allowed researchers to render comprehensible (29) some of the mechanisms responsible for development of herpesviral resistance, an increasing problem in clinics in the treatment of
immunocompromised patients (26-28). Despite the increased structural knowledge, the basis of the molecular difference in substrate and drug
specificity of HSV 1 TK and the particular role of the LID region still
remain unclear. This work reports a study on the nature of mechanism of
binding of HSV 1 TK by means of site-directed mutagenesis combined with
isothermal calorimetric measurements and guided by ab initio
calculations and sequence comparison. It shows the link between the
broad substrate diversity of HSV 1 TK and the presence of structural
features, such as the residue triad His-58/Met-128/Tyr-172, which is
thought to confer distinctive binding of an exceptionally large variety
of substrates to the HSV 1 TK and to guide the catalytic properties.
Furthermore, we give evidence for the importance of the flexible LID
domain for enzyme function.
 |
EXPERIMENTAL PROCEDURES |
Materials--
[methyl-1',2'-3H]Thymidine
(3 TBq/mmol) was obtained from Amersham Pharmacia Biotech, and [side
chain-2-3H]acyclovir (1.2 TBq/mmol) was obtained from NEN
Life Science Products.
3'-Azido-[methyl-3H]deoxythymidine (0.2 TBq/mmol) was purchased from Moravek Biochemicals. Nucleotides and
AmpliTaq GoldTM polymerase were bought from Perkin-Elmer.
Restriction endonucleases, T4 DNA ligase, and thrombin were from
Promega. Reagents for enzyme assays were obtained from Sigma.
Strains and Plasmid--
Strain DH5
(deoR
endA1 recA1 rel A1 gyrA96 thi-1 hsdR17 supE44 lacZ Ä M15
F

)
(CLONTECH) was used for all cloning steps. Strain
BL21 (ompT
, F
, hsdS
(rB
, mB
), gal) (Amersham Pharmacia
Biotech) served as host for expression. The plasmid pGEX-2T was
purchased from Amersham Pharmacia Biotech. The plasmid pBR322-TK
containing the gene for HSV 1 strain F TK was a gift from S. McKnight.
The expression vector pGEX-2T-TK was constructed as described earlier
(30).
Mutagenesis--
Site-directed mutagenesis was performed by
using oligonucleotide-directed polymerase chain reaction based on a
three-primer method (31, 32). The primers were ordered, synthesized,
and purified at Microsynth (Balgach, CH). Briefly, in the first PCR, bacteriophage M13mp18, containing the BamHI-KpnI
fragment of HSV 1 TK, was amplified using the respective antiparallel
mutagenic primer (H58L, 5'-GAC GGT CCC CTC GGG ATG GG-3';
M128I, 5'-CAG ATA ACA ATC GGC ATG CC-3'; M128A, 5'-GCG CCC
AGA TAA CAG CGG GCA TGC CTT ATG C-3'; M128F, 5'-GCG CCC AGA
TAA CAT TCG GCA TGC CTT ATG C-3'; Y172F, 5'-CTC CTG TGC
TTC CCG GCC G-3') and the M13mp universal primer (5'-GCT ATG
ACC ATG TTA CG-3'). The resulting amplification products were
gel-purified and subsequently used as a megaprimer. In the second PCR,
the isolated megaprimer was hybridized to pGEX-2T-TK and extended
within a single PCR cycle. Then, the flanking M13mp universal primer
and pGEX-2T universal primer (5'-GGG CTG GCA AGC CAC GTT TGG TG-3')
were added to the PCR tubes, and 30 PCR cycles were performed. In the
last step, each of the fragments containing the desired mutation was
cloned into the expression vector pGEX-2T-TK by digestion with the
restriction enzymes BamHI and KpnI and subsequent
gel purification and ligation. Additional restriction steps with
BamHI/SacI and BamHI/AccI,
were necessary to obtain the mutants M128F/Y172F, H58L/M128F/Y172F, and
H58L/M128F.
For the mutant E225L, we used a four-primer-based PCR method described
by Innis et al. (33). Basically, two primary PCRs are
performed separately. The mutation is introduced as part of the
respective mutagenic inside primers (forward, 5'-CCC GGG CCT GCG GCT GGA CC-3'; reverse, 5'-GGT CCA GCC GCA GGC CGG
G-3'), each of which is amplified with a suitable outside primer. The two products overlap in sequence; both contain the same mutation. After
gel purification, these overlapping primary products were denatured and
allowed to reanneal together, producing two possible heteroduplex
products. The subsequent reamplification of one of these products with
only the right- and leftmost ("outside") primers resulted in the
enrichment of the full-length, secondary product, which was then
introduced into the vector pGEX-2T-TK, replacing the respective wild
type fragment by SmaI/SacI restriction.
Sequence Verification--
Competent Escherichia coli
DH5
was transfected with the mutated pGEX-2T-TK DNA. After DNA
isolation of several clones, we sequenced the entire TK gene of the
respective mutant progeny, using the dye terminator method (ABI
PRISMTM 310) to verify that the targeted mutation and no
frameshift or additional mutation had occurred.
Expression and Purification of the Mutant HSV 1 TKs--
Competent E. coli BL21 were transformed with the
vector pGEX-2T-TK containing the respective mutated full-length
tk gene as a glutathione S-transferase fusion
protein. Protein expression was induced by the addition of 0.2 mM isopropyl-
-D-thiogalactopyranoside. After
20 h at 25 °C, bacteria were harvested by centrifugation, frozen, thawed, and lysed in buffer (50 mM Tris, pH 7.5, 1 mM phenylmethylsulfonyl fluoride, 10 mM DTT,
10% glycerol, and 1% Triton X-100) in the presence of 150 µg/ml
lysozyme and 2000 units of DNase I (10 mM
MgCl2, 1 mM MnCl2, and 10 mM EDTA for inactivation of DNase I afterward) for 30 min
at 4 °C and by additional sonication for 3 min. The lysate was
clarified by centrifugation at 12,000 × g for 20 min
and subjected to a one-step glutathione-agarose purification procedure
and subsequently to column thrombin cleavage as described (34).
Purification was monitored by SDS-polyacrylamide gel electrophoresis
and led to a >90% pure thrombin-cleaved protein, which was directly
used for kinetic studies. Total protein concentration was measured
using the Bio-Rad protein assay.
Thymidine, Acyclovir, and AZT Kinetics--
Kinetic studies
measuring the conversion of the labeled substrate to substrate
monophosphate were performed using the DEAE-cellulose method as
described earlier (35, 36). Reactions were carried out in a final
volume of 30 µl containing 50 mM Tris, pH 7.2, 5 mM ATP, 5 mM MgCl2, 1.5 mg/ml BSA.
The amount of enzyme and concentrations of 3H-labeled
substrate were chosen in consideration of Michaelis-Menten conditions
for initial velocity measurements. The Km and
Vmax values have been determined by nonlinear
fit of the raw data to the Michaelis-Menten equation using the Microcal
Origin software. kcat values were determined by
dividing Vmax by the enzyme concentration. These
values were measured based on at least three independent assays.
Spectrophotometric Assay for Thymidine Kinase Activity--
A
UV-spectrophotometric test was employed to monitor ADP formation during
substrate phosphorylation. Enzyme activity was measured using a lactate
dehydrogenase-pyruvate kinase-coupled assay (6). The change in
A340 was recorded over time by analyzing mutant TKs and different substrates.
HPLC Assay--
High performance liquid chromatography was
applied to monitor ADP and dTMP, ACVMP, or AZTMP formation during
substrate phosphorylation with ion-pair chromatography using a modified
version of the previously published protocol (37) (Column,
RP-18; solvent, 0.2 M NaH2PO4, 25 mM tetrabutylammonium-hydrogen sulfate, 3% methanol; flow, 1.1 ml/min; detection, UV 254 nm). This method was applied to check
those mutants that could not be measured by either the radioactive or
the UV spectrometric approach. Reactions were carried out in a final
volume of 75 µl containing 50 mM Tris, pH 7.2, 5 mM ATP, 5 mM MgCl2, 2 mM thymidine (ACV/AZT), and 1-5 µg of thymidine kinase.
The reaction was stopped after 1 h at 37 °C by a 10-fold dilution in water and freezing at
20 °C prior to injection. The formation of the nucleotide monophosphate was monitored qualitatively. Two different blank reactions (no enzyme or no substrate) were run
concurrently to account for the occurring minimal reaction independent
ATP hydrolysis. The detection limit for phosphorylated substrate lies
under 20 nmol making this method even more sensitive than the UV assay.
Titration Calorimetry--
To evaluate the binding affinity of
the less active mutants, isothermal titration microcalorimetry (ITC)
was carried out. For stability reasons, all measurements were performed
with the glutathione S-transferase fusion protein because
the biochemical properties are identical to thymidine kinase (34).
After isolation of the fusion protein from the crude extract onto the
glutathione-Sepharose, the protein was directly (on-column) exchanged
into the measuring buffer (50 mM Tris-HCl, pH 7.5, 4 mM EDTA, 5 mM glutathione, 1 mM
DTT, and 1 mM ATP) by thoroughly rinsing the column with an excess amount of buffer. The purified protein was eluted by addition of
5 mM glutathione into the buffer and was directly used for titration experiments. The enzyme concentration was determined using
the Bio-Rad protein assay and was corrected for impurities detected by
SDS-polyacrylamide gel electrophoresis and quantified by gel
densitometry. This purification protocol usually let to a purity of
70-80% of the fusion protein.
Isothermal titration microcalorimetry was performed employing an OMEGA
microcalorimeter from Microcal, Inc. (Northampton, MA), with a cell
volume of 1.3338 ml and using a 100-µl microsyringe while stirring at
375 rpm. The calorimeter and the equations used to fit calorimetric
data have been described in detail previously (38). The reference cell
was filled with water containing 0.01% sodium azide, and the
instrument was calibrated with standard electrical pulses. All ITC
measurements were performed at 25 °C in 50 mM Tris-HCl,
pH 7.5 (at 25 °C), 4 mM EDTA, 5 mM
glutathione, 1 mM DTT, and 1 mM ATP. Prior to
loading into the microcalorimeter, all solutions were degassed for 10 min with gentle swirling under vacuum. Solutions of the fusion protein
were filled in the sample cell and titrated with thymidine with a first
control injection of 1 µl followed by 29 identical injections of 4 µl. Thymidine solutions were prepared by dissolving it in the same
buffer to concentrations generally 25 times higher than the protein
solution. The titration experiment was designed to ensure complete
saturation of the enzyme before the final injection. The heat of
dilution for the ligand was concentration-independent and corresponded very well to the heat observed from the last injections after the
protein was saturated. Therefore, the baseline of the titrations could
usually be well estimated from the last injections of the titration. No
interference of spontaneous DTT oxidation with measurements was
observed. Data were collected, corrected for ligand heats of dilution,
and deconvoluted using the Microcal Origin software supplied with the
instrument to yield binding constants (Ka) and
enthalpies of binding (
H). The thermodynamic parameters
were calculated from the basic equations of thermodynamics:
G =
H
T
S =
RTlnKa, where
G,
H, and
S are the changes in free energy,
enthalpy, and entropy of binding, respectively.
Sequence Alignments--
Sequences were taken from the
GenBankTM data base and were aligned with the aid of the
program multAlin (39).
 |
RESULTS |
Sequence Alignments--
Two sequence motifs
(GXXGXGK and (F)DRH) are highly conserved among
thymidine kinases. The region GXXGXGK corresponds
to the glycine-rich loop (22), which accommodates the ATP-phosphate, and the (F)DRH motif (40) is located in the five-stranded
-sheet core of the protein (18-20). Based on the sequence alignment shown in
Fig. 2, we analyzed the residues that are involved in thymidine fixation and in deoxyribose orientation (Glu-225) (see Fig.
1). Gln-125, Arg-163, and Glu-225 are
highly conserved in all TKs. The succession of His-58, Met-128, and
Tyr-172 in TKs is so far known for four viral strains, namely HSV 1, HSV 2, MHV (Fig. 2), and BHV. Instead, in
most other TKs the combination X-58/Phe-128/Phe-172 is
found, where X can be any hydrophobic amino acid except
histidine. In all the studied TKs, a Tyr at position 172 is never
combined with a Phe at position 128 (HSV 1 TK numbering).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 1.
Representation of a portion of the active
site of HSV 1 TK with bound thymidine. The position and geometry
of dT and the amino acids that are directly involved in substrate
binding are shown as capped sticks and are labeled (18). The
secondary structure of the protein is displayed as tubes.
The hydrogen bond-mediating water molecules are presented as
small spheres, and hydrogen bonds are displayed as
dashed lines. The LID region and P-loop (glycine loop) are
indicated. The figure was prepared using the program SYBYL, version 6.3 (Tripos Associates). The coordinates are indexed as 2VTK in the Protein
Data Bank, Rutgers University.
|
|

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 2.
Multiple alignment of amino acid sequences of
HSV 1 and related virus strains thymidine kinases. Residues of
interest are marked using numbering of HSV 1 TK. Selected excerpts of
TKs from herpes simplex virus types 1 and 2, marmoset herpesvirus
(MHV), equine herpesvirus type 4 (EHV),
varicella-zoster virus (VZV), and Epstein-Barr virus
(EBV) are displayed. Asterisks denote positions
that appear to be completely conserved in all herpesviral TK sequences.
Sequences were taken from the GenBankTM data base.
|
|
Substrate Diversity and Induced Fit--
To address mechanisms
guiding substrate specificity and the role of amino acids in substrate
fixation within the active site of HSV 1 TK, we studied eight different
mutants of HSV 1 TK. Moreover, the role of the negatively charged
Glu-225 sitting within the supposedly moving, otherwise positively
charged LID region, was studied by means of an additional mutant. The
purification and expression scheme allowed rapid isolation of milligram
amounts of wild type and mutant HSV 1 TK enzyme. The two additional
unspecific cleavage sites for thrombin within TK led to a truncated TK,
lacking the N-terminal 33 amino acids that are not essential for
catalytic activity (41).
Previously performed ab initio calculations, using the
Carr-Parinello approach, clearly indicated that the molecular
orbitals of Met-128 and Tyr-172 do not overlap with those of the
substrate, nor are
-
interactions between the Tyr-172 ring and
the substrate present (42). Interestingly, no polarization effect was
found on the Met sulfur atom. This indicated that sulfur has only a hydrophobic effect, although it is a highly polarizable element. Instead, strong polarization effects were located on the substrate, especially on the O and N atoms. Electrostatic interactions between tyrosine and thymine can therefore play an important role in substrate fixation. In order to verify the results and predictions of the ab initio calculations and the alignments, site-directed
mutagenesis at positions 58, 128, and 172 has been performed. The
results of these experiments are summarized in Table
I.
View this table:
[in this window]
[in a new window]
|
Table I
Catalytic properties of mutant HSV 1 TKs on positions 58, 128, and 172
The left column indicates the amino acid change of each mutant. The
kinetic constants (± S.E.) derived in this study are presented in the
next three columns. The right column indicates the pH value above which
full enzyme activity is attained. The values were determined by
nonlinear fit of the raw data to the Michaelis-Menten equation using
the Microcal Origin software. The co-substrate ATP was kept in
10-100-fold excess with regard to its Km value
(Km of ATP, 13 µM). The DEAE paper
method (35) was applied for the kinetic measurements for wild type
M128I, H58L, Y172F, and the triple mutant; for the latter, the
UV-spectrometric assay was also used. + indicates that less than 3% of
the activity with regard to the wt enzyme was detectable, but formation
of dTMP was detectable in HPLC. means that no activity and no
formation of dTMP could be detected with neither method.
|
|
M128A--
The replacement of methionine at position 128 by an
alanine led to a loss of enzyme activity, pointing out the important
role of a rather bulky residue at position 128 for substrate fixation.
M128I--
Interestingly, the exchange of methionine by isoleucine
resulted in the same activity as the wild type enzyme.
M128F--
With phenylalanine at position 128, a completely
inactive enzyme emerged. Even with the HPLC system, no phosphorylated
product was observed.
Y172F--
Exchange of tyrosine 172 to phenylalanine, which
entails the loss of hydrogen bonds to His-58 and Arg-163 (see Fig. 1),
led to an enzyme with an altered activity profile. Under standard kinetic conditions, no explicit progressive thymidine phosphorylation was detectable, but by increasing the pH of the reaction mixture, the
kinetics were measurable, indicating a different pH sensitivity profile
of this mutant in comparison with the wild type enzyme. However, under
the adapted conditions, the Km of the mutant toward
thymidine remained within the same order of magnitude compared with the
wild type.
H58L--
To elucidate the role of His within the context of the
stringent triad His/Met/Tyr, we established the single mutant H58L. Surprisingly, the Km for thymidine was largely
increased (~600-fold), and the reduction in
kcat was about 60-fold. With the UV and HPLC
assays, the phosphorylation of neither deoxycytidine nor acyclovir was detectable.
M128F/Y172F--
Combination of the inactive mutant M128F with
Y172F, creating the "double-F sandwich" enclosing thymidine, did
not show any activity, nor was any phosphorylation detected with the
HPLC assay. To ensure that no hydrophobic collapse was initiated by the
mutations, CD spectra were recorded. However, comparison of mutant CD
spectra with the wild type
spectrum2 revealed no
discrepancy. This particular Phe/Phe-combination is encountered in TKs
(Fig. 2) but with the difference that no His is found at position 58 (HSV 1 TK numbering).
H58L/M128F/Y172F--
Following the indications of the alignment
studies, the His at position 58 in the completely inactive mutant
M128F/Y172F was removed by subcloning to form the triple mutant
H58L/M128F/Y172F. Indeed, the triple mutant turned out to regain
activity and ability to phosphorylate dT with about 600-fold increased
Km. However, the phosphorylation rate was only
reduced 10-fold with regard to the wild type enzyme and significantly
increased compared with single mutant H58L. Attempts to phosphorylate
the guanine nucleoside analog ACV that is a prototype of many other
anti-herpes drugs or deoxycytidine failed even with high amounts of
enzyme using the HPLC assay.
E225L--
In order to explore the role of electrostatic influence
in enhancing or altering substrate binding or the catalytic rate, we
replaced the Glu-225 with the neutral Leu. Glu-225 forms a hydrogen
bond with the 3'-OH of the deoxyribose moiety of dT that is lost by the
mutation. Besides studying the consequence on affinity and velocity of
thymidine kinetics, we analyzed the kinetics with AZT of wild type and
mutant enzyme. The bulky, electron-rich azido group in 3'-position of
AZT offers the possibility to reconnoiter the electrostatic proportions
between active site and the LID region. The resulting effects are
summarized in Table II. The decrease in
kcat and increase in Km of
the mutant toward dT compared with the wild type is more than 1 order
of magnitude. However, E225L reveals the same Km for
both AZT and dT, whereas the catalytic rate of AZT conversion of E225L
is increased compared with dT phosphorylation. The wild type shows an
increased Km and decreased
kcat for AZT phosphorylation, whereas in
contrast, the mutant is capable of increasing the
kcat for AZT, which is the opposite of the
behavior of the wild type. Km for AZT remains within
the same order of magnitude in both enzymes, indicating that the
binding mode for the substrate analog seems not to be altered by the
mutation.
View this table:
[in this window]
[in a new window]
|
Table II
Kinetics of thymidine and AZT phosphorylation of mutant E225L and wild
type HSV 1 TK
The kinetic constants (± S.E.) derived in this study are presented in
the second and third columns. The values have been determined by
nonlinear fit of the raw data to the Michaelis-Menten equation using
the Microcal Origin software. The DEAE paper method (35) was applied
for the kinetic measurements. For AZT kinetics, an additional washing
step of the paper discs with ethanol 100% was necessary to remove
unphosphorylated educt.
|
|
Titration Calorimetry--
We performed titration experiments with
the three mutants including phenylalanine in position 128 to gain
detailed insights into the reasons for the decreased binding
affinities. The results are reported in Table
III. The single replacement of Met-128 by Phe (M128F) resulted in significantly increased entropy of the system,
whereas the enthalpy contribution was diminished. By introduction of
the second Phe, the entropy becomes even more favorable yet is
responsible for establishment of binding. Because both mutants show a
fairly decreased binding enthalpy, it can be suggested that the
development of hydrogen bonds for thymidine is hampered, and therefore
both mutants remain very weak binders. However, by complete
transposition of the triad X-58/Phe-128/Phe-172, the entropy
contribution adapts to the wild type value again, which enables
thymidine to reappoint the correct and therefore productive hydrogen
bonding. However, the binding affinity of the triple mutant remains
reduced by 2 orders of magnitude. These measurements completely agree
with the findings revealed by the kinetic characterization. Namely,
that mutants M128F and M128F/Y172F are barely able to bind
thymidine and thus not successful in phosphorylating dT, whereas
the triple mutant most remarkably regains binding and phosphorylation
ability. For the "inactive" mutants, this method provides even more
accurate information, as they were not distinguishable from each
other with the kinetic measurements.
View this table:
[in this window]
[in a new window]
|
Table III
Thermodynamic data for dT binding in presence of ATP of wild type HSV 1 TK and mutants including Phe at position 128
Isothermal titration microcalorimetry was performed using an OMEGA
microcalorimeter. Data were collected in 50 mM Tris, pH
7.5, 4 mM EDTA, 5 mM glutathione, 1 mM DTT, and 1 mM ATP at 25 °C, corrected for
ligand heats of dilution, and deconvoluted using the Microcal Origin
software supplied with the instrument to yield binding constants
Ka and G, H, and
S, which are the changes in free energy, enthalpy, and
entropy of binding, respectively. The results of the least-squares fit
assuming a single site binding model are displayed.
|
|
 |
DISCUSSION |
To study binding properties and mechanisms, the possibility of
purifying mutants with impaired binding affinities was an important issue. Our one-step purification protocol addressed this issue properly
and was a very convenient method, allowing the purification of TK
mutants not amenable to the conventional thymidine affinity resins. The
subsequent thrombin cleavage led to a >90% pure thrombin-cleaved protein.
Sequence alignments have detected similarities between herpesvirus TKs
and human dCK (16), and to a lesser extent cellular TmpK (17). Such
similarity suggests a common ancestry of HSV TK and cellular dCK or
cellular dTmpK, although the mechanisms by which herpesviruses have
acquired these genes can only be speculated upon. The superimposition
of over 100 amino acids of HSV TK with the recently published crystal
structures of E. coli and yeast dTmpK (43, 44) reveals
striking structural similarity, the latter divided into the same
structural type dTmpK as cellular dTmpKs (45). The root mean square
deviation values are markedly low, with a value of 2.5 Å, when the
glycine-rich loop and the five-stranded
-sheets of yeast dTmpK and
HSV 1 TK were superimposed. Moreover, by this superimposition, the
overall three-dimensional structure of HSV 1 TK, with the exception of
the region between amino acid 250 and 320, was also nicely fitting to
the shorter dTmpK. A closer look at yeast and E. coli dTmpK
revealed, not unexpectedly, a similar binding mode for the nucleobase
compared with HSV 1 TK, namely Phe-69 and the C
of Ser-98
sandwiching thymine (yeast numbering). Such meaningful structural
similarity suggests, even more convincingly than sequence alignments,
the evolutionary relationship among herpesviral TKs and dTmpK.
Unfortunately, to date no such material is available for dCK.
Despite the progress made in understanding detailed aspects of HSV 1 TK
ligand binding, several key questions regarding the broad substrate
diversity remain unresolved. In our attempt to rationalize this
property, we have designed a series of HSV 1 TK mutants at the
positions 58, 128, and 172 and characterized their biochemical and
physicochemical properties. For the comparison of the binding behavior
of the different mutants, the Michaelis constant Km
has been used as binding constant because it has been previously shown
that Km of dT (Km = 0.2 µM) and ACV (Km = 200 µM) correspond to the dissociation constants of dT
(K2 = 0.139 µM) and ACV
(K5 = 162 µM) (46). Furthermore,
for ACV, the Km value of 0.2 mM (Table
I) corresponds with the Ki values ranging from 100 to 200 µM reported in the literature (47-49). This
represents a peculiarity of HSV 1 TK by which dT is binding prior to
ATP, and the rate constant of disintegration of the intermediate
complex (ES) is negligible as compared to the corresponding
dissociation rate constant (46).
In our study, it is noteworthy that no mutation affecting an amino acid
hydrogen bonding thymidine was introduced. The combination of His-58,
Tyr-172, and Met-128 in TK is hitherto only found in four viral
strains, namely HSV 1, HSV 2, MHV, and BHV, causing an extensive broad
substrate acceptance toward both, the sugar and base moiety of the
nucleoside. Instead, in TKs that are more limited in phosphorylation
with respect to the base and/or sugar moiety (50-52), the combination
X-58/Phe-128/Phe-172 is found, where X can be
Tyr, Phe, Ile, Met, or Pro, which are all hydrophobic. Our results
emphasize the extreme sensitivity of substrate affinity on mutational
changes at positions 58, 128, and 172 of HSV 1 TK.
At position 128, we have shown the role of sulfur to be purely
hydrophobic. The M128I mutant constitutes a bio-isosterical modification of the wild type exhibiting almost identical affinity for
thymidine and substrate analog drug ACV. This is in full agreement with
previous theoretical investigations (42). We conclude that a modulation
of residue size in the hydrophobic pocket at position 128 has a direct
impact on binding affinity. As expected, the mutant M128A loses
biological activity, which is an indication that the small alanine side
chain is not sufficient to stabilize the thymine within the active
site. The analysis of the structure suggests that the retained activity
minimum is probably due to a partial compensation of the missing methyl
group (C
) of Met-128 by C
of Ile-97 through dynamic
rearrangements. Instead, the loss in biological activity of the M128F
mutant is due to unproductive orientation of weakly bound thymidine, as
our ITC measurements clearly indicate. The nature of the sandwich-like
complex is modified by the introduction of the bulky Phe-128 into the
available space provided by surrounding hydrophobic amino acids (namely
Trp-88, Thr-96 (C
), Ile-97, and Ile-100). This finding is further
supported by the fact that the combination of Phe-128/Tyr-172 (HSV 1 TK numbering) sandwiching thymidine has not been found so far in any TK
sequence. Additionally, the mutant with the triad
Leu-58/Phe-128/Tyr-172, another combination that does not exist in
nature, shows only barely detectable dT phosphorylation.2
The alteration of the flexibility of the system represented by the
entropy difference between mutant and wild type may explain experimental findings showing that the mutant M128F is not able to
phosphorylate thymidine. Further evidence is added by ITC measurements of this mutant in absence of ATP. The resulting binding enthalpies are
the same as when titrated in the presence of
ATP.3 In contrary, a
substantial difference in binding affinities can be measured with the
wild type enzyme under the same experimental conditions, suggesting an
extended induced fit.4 These
results imply an altered or impaired binding site for ATP in the mutant.
Similarly, the double mutant M128F/Y172F is not able to enforce
catalytic turnover. The adaptation of a second Phe in the mutant
M128F/Y172F even changed the sign of the entropy term, giving a hint of
a favorably preformed binding pocket and of a reduction of the induced
fit movement. However, the establishment of hydrogen bonds for the
substrate seems to be severely impaired by this arrangement, with a
more than 10-fold reduction in binding enthalpy. It can be learned from
the sequence alignments that the Phe-Phe combination indeed exists, but
not with a mutual His in the P loop region. In the mutants discussed
above, the possibility for a reorganization upon thymidine binding is
greatly impaired indicated by the already advantageous entropy of
binding. Rather, removal of His is prerequisite to productive binding.
The mode of binding seems to be enthalpy forced for wild type and
triple mutant TK and entropy driven with M128F/Y172F.
Most striking, an additional mutation, H58L, introducing a hydrophobic
leucine at the histidine position, recovers catalytic activity in the
M128F/Y172F mutant. Interestingly, the exchange of
His-58/Met-128/Tyr-172 to Leu-58/Phe-128/Phe-172 results in a mutant
enzyme the specificity of which is mainly based on a general loss in
affinity. We observed catalytic activity only toward the natural
substrate, indicating a developing resistance toward purine nucleoside
analogs. The rationale for the severely reduced affinity must lie in a
different orientation of the base, as all the amino acids that form
hydrogen bonds with dT or guanine (20) are still present. This is
corroborated by our ITC measurements, revealing a
S similar to wild
type, which indicates a restored flexibility of the enzyme. From the
results, we believe the His-58/Met-128/Tyr-172 triad to be responsible
for a better hydrophobic fit to natural substrates, allowing the
occurrence of the successive movement for completing the catalytic
cycle. As we have shown, residue 58 plays a central role in the
formation of a hydrophobic pocket in a catalytically active mutant
enzyme. However, the understanding of the functional role of His-58 in
the binding process is not fully settled yet.
Nonetheless, on the basis of our study, we may postulate some
functional roles. As can be seen in Fig. 1, the exchange of histidine
58 will presumably affect the orientation of the ribose part of the
substrate. A structural variation at position 58 could indeed allow a
reorientation of the ribose part, being responsible for the recovered
catalytic activity in the triple mutant. His-58, positioned between
Glu-225 and Glu-83, may also serve as transmitter of electron density
and therefore play a central role in catalysis (together with Glu-225
and Glu-83) and electrostatics (hydrogen bond with Tyr-172) within the
active site. However, the structural data and ab initio
calculation that are so far available do not yet provide sufficient
information on the role of this residue.
The mutant E225L, belonging to the LID domain, gives further support
for the involvement of movement and electrostatic interaction. In the
structure, Glu-225 is, together with Glu-83, the only negatively charged amino acid within a cluster of positively charged residues. Glu-225 forms a hydrogen bond with the 3'-OH of the deoxyribose moiety,
which is broken by the mutation. However, the hydrogen bond of Tyr-101
to the 3'-OH is preserved (Fig. 1). The loss in affinity for dT might
be explained by the missing hydrogen bond, but not the decrease in
velocity. The catalytic rate is severely reduced, although all amino
acids (other than Glu-225) that are involved in nucleobase binding and
all the amino acids (Glu-83 and Arg-163) that are apparently involved
in catalysis are disposable. Strikingly, the
kcat of AZT phosphorylation is faster than the kcat for dT, whereas for the wild type, the
opposite situation has been noticed. In TKs, the
-phosphate of ATP
and 5'-OH of deoxyribose need to be activated for the catalytic
reaction. This is achieved by clusters of positive charges from the LID
domain (Arg and Lys) and the Mg2+, making the phosphorus
atom amenable for an nucleophilic attack of the polarized 5'-O, which
is positioned between Glu-225 and Glu-83 (19) and needs to be
negatively charged. During AZT phosphorylation, Glu-225 of wild type
HSV 1 TK is displaced by the bulky 3'-azido group of AZT (53), which
leads to a reduction of polarization of the 5'-O, with a consequent
decrease in velocity. In the E225L mutant, the decline in velocity lies
within the same order of magnitude. This finding suggests that either
displacement or removal of the negative charge (Glu-225) results in an
equal effect. By searching for similar features in dTmpK, we found
Asp-14 in yeast and Glu-12 in E. coli dTmpK that might take
over the function of both Glu-225 and Glu-83 in polarizing 3'-OH of the
deoxyribose and of one oxygen of the
-phosphate of dTMP.
It is noteworthy that our mutagenesis study on the triad involved
residues without direct hydrogen bond contact with the substrate, underscoring the capability of hydrophobic contacts and electrostatics. The residues maintaining direct hydrogen bonds, rather, guide resistance patterns (29). Our results emphasize the extreme sensitivity
of substrate affinity and diversity on mutational changes at the HSV 1 TK positions 58, 128, and 172. This finding is in complete agreement
with our sequence alignment study, indicating the residue triad His-58,
Tyr-172, and Met-128 to be a common motif in thymidine kinases with
broad substrate diversity, whereas variations at these positions, which
correspond to the X-58/Phe-128/Phe-172 HSV 1 TK mutations,
are a common feature for enzymes with restricted substrate acceptance.
Our findings indicate that the existence of a structurally flexible
sandwich complex and the maintenance of balanced electrostatics are
crucial for substrate diversity in HSV 1 TK and a plausible
evolutionary pattern. Therefore, we add a new piece of information for
the design of new antiviral drugs and modified TKs for gene therapy of
cancer and AIDS.
 |
ACKNOWLEDGEMENTS |
We thank Dr. I. Jelesarov for constructive
discussion and technical assistance with the ITC measurements, U. Kessler for aid with the HPLC, F. Seegy for assistance with the
figures, and P. Pospisil for support in the structural comparison of dTmpK.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
41-1-635-6071; Fax: 41-1-635-6884; E-mail:
scapozza@pharma.ethz.ch.
2
B. D. Pilger, unpublished observation.
3
R. Perozzo, unpublished observation.
4
R. Perozzo, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
HSV 1, herpes
simplex virus type 1;
TK, thymidine kinase;
dT, thymidine;
dC, deoxycytidine;
dCK, deoxycytidine kinase;
dTMP, thymidine
monophosphate;
TmpK, thymidylate kinase;
ACV, acyclovir;
PCR, polymerase chain reaction;
DTT, DL-dithiothreitol;
HPLC, high performance liquid chromatography;
AZT, 3'-azidodeoxythymidine;
ITC, isothermal titration
microcalorimetry.
 |
REFERENCES |
| 1.
|
Chen, M. S.,
and Prusoff, W. H.
(1978)
J. Biol. Chem.
253,
1325-1327[Abstract/Free Full Text]
|
| 2.
|
Chen, M. S.,
Summers, W. P.,
Walker, J.,
Summers, W. C.,
and Prusoff, W. H.
(1979)
J. Virology
30,
942-945[Abstract/Free Full Text]
|
| 3.
|
Koonin, E. V.,
and Senkevich, T. G.
(1992)
Virus Genes
6,
187-196[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Cheng, Y. C.,
Huang, E. S.,
Lin, J. C.,
Mar, E. C.,
Pagano, J. S.,
Dutschman, G. E.,
and Grill, S. P.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
2767-2770[Abstract/Free Full Text]
|
| 5.
|
Elion, G. B.,
Furman, P. A.,
Fyfe, J. A.,
de Miranda, P.,
Beauchamp, L.,
and Schaeffer, H. J.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5716-5720[Abstract/Free Full Text]
|
| 6.
|
Keller, P. M.,
Fyfe, J. A.,
Beauchamp, L.,
Lubbers, C. M.,
Furman, P. A.,
Schaeffer, H. J.,
and Elion, G. B.
(1981)
Biochem. Pharmacol.
30,
3071-3077[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Culver, K. W.,
Van Gilder, J.,
Link, C. J.,
Carlstrom, T.,
Buroker, T.,
Yuh, W.,
Koch, K.,
Schabold, K.,
Doornbas, S.,
and Wetjen, B.
(1994)
Hum. Gene Ther.
5,
343-379[Medline]
[Order article via Infotrieve]
|
| 8.
|
Tong, X. W.,
Agoulnik, I.,
Blankenburg, K.,
Contant, C. F.,
Hasenburg, A.,
Runnebaum, L. B.,
Stickeler, E.,
Kaplan, A. L.,
Woo, S. L.,
and Kieback, D. G.
(1997)
Anticancer Res.
17,
811-813[Medline]
[Order article via Infotrieve]
|
| 9.
|
Caruso, M.,
and Bank, A.
(1997)
Virus Res.
52,
133-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Bonini, C.,
Ferrari, G.,
Verzeletti, S.,
Servida, P.,
Zappone, E.,
Ruggieri, L.,
Ponzoni, M.,
Rossini, S.,
Mavilio, F.,
Traversari, C.,
and Bordignon, C.
(1997)
Science
276,
1719-1724[Abstract/Free Full Text]
|
| 11.
|
Jacobson, J. G.,
Chen, S. H.,
Cook, W. J.,
Kramer, M. F.,
and Coen, D. M.
(1998)
Virology
242,
161-169[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Efstathiou, S.,
Kemp, S.,
Darby, G.,
and Minson, A. C.
(1989)
J. Gen. Virol.
70,
869-879[Abstract/Free Full Text]
|
| 13.
|
Coen, D. M.,
Kosz-Vnenchak, M.,
Jacobson, J. G.,
Leib, D. A.,
Bogard, C. L.,
Schaffer, P. A.,
Tyler, K. L.,
and Knipe, D. M.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
4736-4740[Abstract/Free Full Text]
|
| 14.
|
Chen, S. H.,
Cook, W. J.,
Grove, K. L.,
and Coen, D. M.
(1998)
J. Virol.
72,
6710-6715[Abstract/Free Full Text]
|
| 15.
|
Bradshaw, H. D., Jr.,
and Deininger, P. L.
(1984)
Mol. Cell. Biol.
4,
2316-2320[Abstract/Free Full Text]
|
| 16.
|
Harrison, P. T.,
Thompson, R.,
and Davison, A. J.
(1991)
J. Gen. Virol.
72,
2583-2586[Abstract/Free Full Text]
|
| 17.
|
Robertson, G. R.,
and Whalley, J. M.
(1988)
Nucleic Acids Res.
16,
11303-11317[Abstract/Free Full Text]
|
| 18.
|
Wild, K.,
Bohner, T.,
Aubry, A.,
Folkers, G.,
and Schulz, G. E.
(1995)
FEBS Lett.
368,
289-292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Wild, K.,
Bohner, T.,
Folkers, G.,
and Schulz, G. E.
(1997)
Protein Sci.
6,
2097-2106[Abstract]
|
| 20.
|
Brown, D. G.,
Visse, R.,
Sandhu, G.,
Davies, A.,
Rizkallah, P. J.,
Melitz, C.,
Summers, W. C.,
and Sanderson, M. R.
(1995)
Nat. Struct. Biol.
2,
876-881[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Muller, C. W.,
Schlauderer, G. J.,
Reinstein, J.,
and Schulz, G. E.
(1996)
Structure
4,
147-156[Medline]
[Order article via Infotrieve]
|
| 22.
|
Liu, Q. Y.,
and Summers, W. C.
(1988)
Virology
163,
638-642[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Munir, K. M.,
French, D. C.,
Dube, D. K.,
and Loeb, L. A.
(1992)
J. Biol. Chem.
267,
6584-6589[Abstract/Free Full Text]
|
| 24.
|
Munir, K. M.,
French, D. C.,
Dube, D. K.,
and Loeb, L. A.
(1994)
Protein Eng.
7,
83-89[Abstract/Free Full Text]
|
| 25.
|
Balasubramaniam, N. K.,
Veerisetty, V.,
and Gentry, G. A.
(1990)
J. Gen. Virol.
71,
2979-2987[Abstract/Free Full Text]
|
| 26.
|
Englund, J. A.,
Zimmerman, M. E.,
Swierkosz, E. M.,
Goodman, J. L.,
Scholl, D. R.,
and Balfour, H. H., Jr.
(1990)
Ann. Intern. Med.
112,
416-422
|
| 27.
|
Darby, G.,
Field, H. J.,
and Salisbury, S. A.
(1981)
Nature
289,
81-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Gaudreau, A.,
Hill, E.,
Balfour, H. H., Jr.,
Erice, A.,
and Boivin, G.
(1998)
J. Infect. Dis.
178,
297-303[Medline]
[Order article via Infotrieve]
|
| 29.
|
Kussmann-Gerber, S.,
Kuonen, O.,
Folkers, G.,
Pilger, B. D.,
and Scapozza, L.
(1998)
Eur. J. Biochem.
255,
472-481[Medline]
[Order article via Infotrieve]
|
| 30.
|
Michael, M.,
Gerber, S.,
Fetzer, J.,
and Folkers, G.
(1997)
Pharm. Acta Helv.
72,
139-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Steinberg, R. A.,
and Gorman, K. B.
(1994)
Anal. Biochem.
219,
155-157[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Barettino, D.,
Feigenbutz, M.,
Valcarcel, R.,
and Stunnenberg, H. G.
(1994)
Nucleic Acids Res.
22,
541-542[Free Full Text]
|
| 33.
|
Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J.
(eds)
(1990)
PCR Protocols: A Guide to Methods and Application
, pp. 177-183, Academic Press Inc., San Diego
|
| 34.
|
Fetzer, J.,
Michael, M.,
Bohner, T.,
Hofbauer, R.,
and Folkers, G.
(1994)
Protein Expression Purif.
5,
432-441[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Gerber, S.,
and Folkers, G.
(1996)
Biochem. Biophys. Res. Commun.
225,
263-267[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Furlong, N. B.
(1963)
Anal. Biochem.
5,
515-522[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Masson, S.,
Desmoulin, F.,
Sciaky, M.,
and Cozzone, P. J.
(1993)
Biochemistry
32,
1025-1031[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Wiseman, T.,
Williston, S.,
Brandts, J. F.,
and Lin, L. N.
(1989)
Anal. Biochem.
179,
131-137[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Corpet, F.
(1988)
Nucleic Acids Res.
16,
10881-10890[Abstract/Free Full Text]
|
| 40.
|
Folkers, G.,
and Trumpp, S.
(1987)
Med. Sci. Res.
15,
1495-1496
|
| 41.
|
Halpern, M. E.,
and Smiley, J. R.
(1984)
J. Virol.
50,
733-738[Abstract/Free Full Text]
|
| 42.
|
Alber, F.,
Kuonen, O.,
Scapozza, L.,
Folkers, G.,
and Carloni, P.
(1998)
Proteins
31,
453-459[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Lavie, A.,
Vetter, I. R.,
Konrad, M.,
Goody, R. S.,
Reinstein, J.,
and Schlichting, I.
(1997)
Nat. Struct. Biol.
4,
601-604[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Lavie, A.,
Ostermann, N.,
Brundiers, R.,
Goody, R. S.,
Reinstein, J.,
Konrad, M.,
and Schlichting, I.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14045-14050[Abstract/Free Full Text]
|
| 45.
|
Lavie, A.,
Konrad, M.,
Brundiers, R.,
Goody, R. S.,
Schlichting, I.,
and Reinstein, J.
(1998)
Biochemistry
37,
3677-3686[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Kussmann-Gerber, S.,
Wurth, C.,
Scapozza, L.,
Pilger, B. D.,
Pliska, V.,
and Folkers, G.
(1999)
Nucleosides Nucleotides
18,
311-330[Medline]
[Order article via Infotrieve]
|
| 47.
|
Fyfe, J. A.,
McKee, S. A.,
and Keller, P. M.
(1983)
Mol. Pharmacol.
24,
316-323[Abstract]
|
| 48.
|
Larder, B. A.,
Cheng, Y. C.,
and Darby, G.
(1983)
J. Gen. Virol.
64,
523-532[Abstract/Free Full Text]
|
| 49.
|
Larder, B. A.,
Derse, D.,
Cheng, Y. C.,
and Darby, G.
(1983)
J. Biol. Chem.
258,
2027-2033[Abstract/Free Full Text]
|
| 50.
|
Abele, G.,
Cox, S.,
Bergman, S.,
Lindborg, B.,
Vissgarden, A.,
Karlström, A.,
Harmenberg, J.,
and Wahren, B.
(1991)
Antiviral Chem. Chemother.
2,
163-169
|
| 51.
|
Roberts, G. B.,
Fyfe, J. A.,
McKee, S. A.,
Rahim, S. G.,
Daluge, S. M.,
Almond, M. R.,
Rideout, J. L.,
Koszalka, G. W.,
and Krenitsky, T. A.
(1993)
Biochem. Pharmacol.
46,
2209-2218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Gustafson, E. A.,
Chillemi, A. C.,
Sage, D. R.,
and Fingeroth, J. D.
(1998)
Antimicrob. Agents Chemother.
42,
2923-2931[Abstract/Free Full Text]
|
| 53.
|
Christians, F.,
Scapozza, L.,
Crameri, A.,
Folkers, G.,
and Stemmer, P. W.
(1999)
Nat. Biotechnol.
17,
259-264[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. D. Graci, D. A. Harki, V. S. Korneeva, J. P. Edathil, K. Too, D. Franco, E. D. Smidansky, A. V. Paul, B. R. Peterson, D. M. Brown, et al.
Lethal Mutagenesis of Poliovirus Mediated by a Mutagenic Pyrimidine Analogue
J. Virol.,
October 15, 2007;
81(20):
11256 - 11266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Andrei, J. Balzarini, P. Fiten, E. De Clercq, G. Opdenakker, and R. Snoeck
Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin
J. Virol.,
May 1, 2005;
79(9):
5863 - 5869.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Welin, U. Kosinska, N.-E. Mikkelsen, C. Carnrot, C. Zhu, L. Wang, S. Eriksson, B. Munch-Petersen, and H. Eklund
Structures of thymidine kinase 1 of human and mycoplasmic origin
PNAS,
December 28, 2004;
101(52):
17970 - 17975.
[Abstract]
[Full Text]
[PDF]
|
 |
|